Glazer Capital LLC’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Glazer Capital LLC’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.6M	Sell	999,899 -678,507	-40%	-$7.18M	0.26%	77
2026 Q1	$17.6M	Sell	1,678,406 -138,022	-8%	-$1.44M	0.37%	43
2025 Q4	$18.8M	Sell	1,816,428 -5,864	-0.3%	-$60.5K	0.5%	39
2025 Q3	$18.7M	Sell	1,822,292 -158	-0%	-$1.62K	0.63%	39
2025 Q2	$18.6M	Sell	1,822,450 -502	-0%	-$5.08K	0.66%	30
2025 Q1	$18.3M	Buy	+1,822,952	New	+$18.2M	0.85%	30

Other funds holding DMAA

KIM

Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

SAMU

SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return

Glazer Capital LLC's DMAA Position: Q2 2026 in Review

Glazer Capital LLC reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 40% in Q2 2026, selling an estimated $7.18M and leaving 999,899 shares worth $10.6M. The position accounts for 0.26% of the portfolio, ranked #77.

Glazer Capital LLC first reported a position in DMAA in Q1 2025 and has held it in 6 quarters since. The position peaked at $18.8M in Q4 2025. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

Glazer Capital LLC held 999,899 shares of Drugs Made In America Acquisition Corp worth $10.6M as of Q2 2026.
Glazer Capital LLC sold 678,507 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $7.18M.
Drugs Made In America Acquisition Corp made up 0.26% of Glazer Capital LLC's portfolio in Q2 2026, its #77 holding.
Glazer Capital LLC first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and has held it in 6 quarters since.
Glazer Capital LLC's Drugs Made In America Acquisition Corp position peaked at $18.8M in Q4 2025.
23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Glazer Capital LLC's 13F filing for Q2 2026, filed 17 Aug 2026.